Trial record 1 of 1 for:    ascend tysabri
Previous Study | Return to List | Next Study

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

This study has been terminated.
(The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.)
Information provided by (Responsible Party):
Biogen Identifier:
First received: July 21, 2011
Last updated: November 12, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: April 2016
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)